Abstract
Cancer immunotherapy has become a therapeutic routine in increasing number of diagnoses. Beside the established antitumoral efficacy, a range of specific adverse events is now well-known including the immunological basis of the evolution.
The article summarizes the most frequent types of skin toxicity in immunotherapy. Severity assessment is presented according to the new version of CTCAE (Common Terminology Criteria for Adverse Events).
Current recommendations of ESMO (European Society for Medical Oncology) and NCCN (National Comprehensive Cancer Network) are taken into account in the treatment management.